prognostic value and may be a useful tool for the new therapeutic strategies aimed at eradicating the HBV infection.
Introduction
The amount of intrahepatic total HBV DNA (it-HBV DNA) is an important parameter reflecting the extent of viral spread in liver tissue, and it represents a valuable marker of the histological status of the liver. Indeed, intrahepatic levels of HBV DNA have been associated with liver inflammation and injury [2, 16] . Among patients with hepatocellular carcinoma, previous studies have demonstrated that higher level of it-HBV DNA correlates with a greater recurrence rate and poor overall survival after resection [13, 15] . Consequently, the evaluation of it-HBV DNA in liver biopsies after resection or transplantation can be a useful parameter for identifying HCC patients at higher risk of recurrence, at need of a more careful liver monitoring.
The HBV DNA content inside the liver may also give an insight into the prognosis [2] and would be a useful marker for assessing the success of the new therapeutic strategies aiming at eradicating HBV infection.
It-HBV DNA may also be beneficial for the diagnosis of occult hepatitis B (OBI), actually defined as the presence of viral DNA in the liver tissue (regardless of HBV DNA detectability in serum) of individuals testing negative for serum HBsAg. OBI may have clinical impacts on the possibility of transmission of HBV infection, risk of viral reactivation, contribution to liver disease progression and development of hepatocellular carcinoma (HCC) [3, 4, 7, 11, 14] . OBI diagnosis can be particularly relevant in the Abstract Intrahepatic total HBV DNA (it-HBV DNA) level might reflect the size of virus reservoir and correlate with the histological status of the liver. To quantitate it-HBV DNA in a series of 70 liver biopsies obtained from hepatitis B chronic patients, a modified version of the COBAS ® Ampliprep/COBAS ® TaqMan HBV test v2.0 was used for this purpose. The linearity and reproducibility of the modified protocol was tested by quantifying serial dilutions of a full-length HBV containing plasmid and it-HBV DNA from a reference patient. A good linear trend between the expected values and those generated by the assay was observed at different concentrations of both plasmid and reference patient (R 2 = 0.994 and 0.962, respectively). Differences between the values obtained in two independent runs were ≤0.3 log IU for the plasmid and ≤0.6 log IU/mg for the reference patient, showing a high inter-run reproducibility. In the 70 liver biopsies, it-HBV DNA level ranged from 1. 
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setting of liver transplantation (LT). Indeed, OBI positivity in liver grafts (if not properly treated) may be responsible for de novo hepatitis B after LT, elicited by the state of immunosuppression in the recipients. Yet, a timely recognition of OBI by detection of it-HBV DNA in liver graft can be crucial in the setting of donor LT in order to refine the allocation process of liver grafts harvested from donors with OBI [8] .
Although numerous in-house quantitative methods for detecting and quantifying it-HBV DNA have been published [2, 6, 9] , no standardized assay is still commercially available for its measurement in liver biopsies. In this study, we describe a method for the quantitation of it-HBV DNA. In particular, we attempted to quantify it-HBV DNA using a modified protocol of the of COBAS ® Ampliprep/ COBAS ® TaqMan HBV test, v2.0.
Materials and methods
It-HBV DNA, extracted from liver biopsies obtained from 70 HBV chronically infected patients, was quantified by applying a modification in the protocol of COBAS ® Ampliprep/COBAS ® TaqMan HBV test, v2.0, designed to extract and quantify HBV DNA starting from patients' sera (Roche Molecular System, Inc., Branchburg, NJ, USA). In particular, viral and genomic DNA was extracted from 10 mg of liver biopsies [stored in the stabilizing medium RNAlater (QIAGEN, Hilden, Germany)] using the DNeasy Blood & Tissue Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Extracted DNA was eluted with 100 µL elution buffer and quantified with the fluorometer Qubit 2.0 (Life Technologies, Invitrogen Division, Darmstadt, Germany). Then, 10 µl of extracted DNA was suspended in 790 µl of virus-free serum. The obtained 800 µl volume was then loaded on the COBAS ® Ampliprep/COBAS ® TaqMan instrument for HBV DNA quantitation as requested by the methodology. Before testing the liver biopsies, the linearity and reproducibility of the modified protocol was first tested by using serial dilutions of the full-length HBV genome-encoding plasmid pAM6 (ATCC ® 45020D™ ATCC, Manassas, VA), diluted at the concentrations of 6.3 log IU, 5.3 log IU, 4.3 log IU, 3.3 log IU, 2.3 log IU, 1.3 log IU and 5 IU. Following this experiment, the linearity and reproducibility of the modified protocol was then tested by using serial dilutions (from 6 to 1 log IU) of HBV DNA of a reference patient.
The quantification of the above-mentioned HBV standards and of it-HBV DNA from patients' biopsies was performed in two independent amplifications, each in triplicate.
Considering that 100 µl of extracted DNA was obtained from 10 mg of tissue, and that 10 µl of the extract (thus representing the amount of DNA that is present in 1 mg of tissue) was used for the quantification of it-HBV DNA, all concentrations of it-HBV DNA were converted into IU/mg of liver tissue.
The study was approved by the local ethics committee (Comitato Etico Indipendente, President Prof. Maria Grazia Marciani), study protocol FIRB (RBAP11YS7K), register experimentations 168/13. Research was carried out according to the Helsinki Declaration. Informed consent was obtained from the patients involved in the study. All patients are adults.
Results

HBV standards quantification
Testing the plasmid pAM6, a linear relationship was observed between the expected values and those generated by the assay. Indeed, the R 2 value was 0.994 indicating a good accuracy of the method (Fig. 1a) . In particular, the difference between the observed and expected values was always ≤0.2 log IU at all the analysed concentrations (from 6.3 log IU to 1.3 log IU of HBV DNA). The lowest concentration (5 IU of pAM6) was tested in quadruplicate, resulting not detectable in two cases and detected but <20 IU in the other two tests.
When the inter-run reproducibility was tested, the analysis of the data demonstrated a high reliability of the method, with differences between the values obtained in two independent runs that never exceeded the 0.3 log IU, at all the analysed concentrations (Fig. 1b) . The coefficient of variation (CV) for repeat runs was 1.87 ± 0.12%.
It-HBV DNA quantification from a reference patient
Considering the different concentrations of it-HBV DNA from a reference patient, the relationship between the observed and expected values showed a good linear trend with R 2 of 0.962 (Fig. 2a) . As shown in Fig. 2b , the inter-run variability of the reference patient is low, highlighting a good inter-run reproducibility of the assay. Indeed, the differences between the values obtained in two independent runs fell within the limit of 0.6 log IU/mg, at all the analysed concentrations, with higher divergences for lower concentrations (from 2.0 to 4.0 log IU/mg). Moreover, in each run, the differences between the expected and the observed values were always within the limit of 0.5 log IU/mg. The CV for repeat runs was 0.83 ± 0.05%. Finally, the lowest concentration tested (1 log IU/mg) was always detected but below the limit of quantification of the assay (<20 IU/mg).
It-HBV DNA from a population of HBV chronically infected patients
It-HBV DNA was then quantified in liver biopsies from 70 HBV chronically infected patients. The demographic and virological characteristics of these patients are reported in Table 1 . Most patients were male (75.7%), with a median age (IQR) of 34.5 (28.5-41.8) years; median serum HBV DNA (IQR) and median ALT (IQR) were 3.7 (2.8-4.8) log IU/ml and 36 (24-51) U/l, respectively. The majority of patients were infected by HBV genotype D (33, 47.1%) followed by genotypes C (14, 20%), A (10, 14.3%), E (9, 12.9%) and B (4, 5.7%). No HIV or HDV co-infections were present.
It-HBV DNA was detected in 70/70 liver biopsies with a quantification ranging from 1.4 log IU/mg to a maximum of 5.4 log IU/mg. Figure 3 shows a good linearity and reproducibility between values obtained in two different runs. In 
Discussion
New therapeutic approaches have been proposed which aim at curing HBV infection through eradication of covalently closed circular DNA (cccDNA) in liver cells [1, 10] . Molecular methods able to measure the targets of these novel therapies would be crucial for assessing their success and confirm the cccDNA eradication. In this study, we showed that the modified version of COBAS ® Ampliprep/ COBAS ® TaqMan HBV test v2.0, an optimized and commercially available kit for quantification of serum HBV DNA, has a good accuracy, reproducibility and sensitivity also when used for measuring it-HBV DNA extracted from liver biopsies, as demonstrated by testing a wide range of HBV DNA levels. These technical features along with a good genotype inclusivity make this modified version of the Roche assay potentially suitable for determining disease activity and/or viral replication inside the hepatocytes, helping to guide the management of HBV-infected patients.
Currently, quantification of it-HBV DNA as a marker of viral replication inside the liver is not performed on a regular basis; however, its determination might have clinical relevance in chronically HBV-infected patients with suppressed viremia where intrahepatic quantification of HBV DNA could provide information about the size of viral reservoir and guide antiviral therapy. Indeed, despite the current therapy with nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) is highly effective in eliminating circulating HBV DNA in the overwhelming majority of HBVinfected patients, it is unable to completely block intracellular viral DNA synthesis, with a consequent persistence of HBV DNA in the liver that could result in a continuous replenishment of the cccDNA pool [5] .
In addition, the detection of it-HBV DNA represents the most reliable marker for an accurate OBI diagnosis [17] . Particularly in the setting of LT, OBI diagnosis by detection and quantification of it-HBV DNA levels in liver donors can be crucial for an adequate risk management of de novo hepatitis B in LT recipients [8] .
Recently, it-HBV DNA has been investigated in relation to HBsAg and HBeAg titters and serum HBV DNA levels in both HBeAg-positive and HBeAg-negative chronic patients (15) [12] . Cacciola et al. [6] investigated it-HBV DNA in HBsAg-positive chronic patients with detectable or suppressed viral replication, and in HBsAgnegative patients with occult HBV infection. Despite lowlevel viremia, significant amount of it-HBV DNA can be detected inside the hepatocytes suggesting a possible involvement in viral reactivation after therapy interruption. Finally, an association between the severity of liver fibrosis and level of it-HBV DNA has been reported [16] . In particular, it has been recently demonstrated that a higher amount of it-HBV DNA correlates with a more severe degree of necroinflammation and increased levels of serum ALT, suggesting that an increased intracellular virus burden can be responsible for inducing immune-mediated damage and necroinflammation in the liver [15] . Thus, the scientific literature suggests the importance of measuring intrahepatic HBV DNA level to get insights into the pathogenesis of disease and patients' prognosis.
The study presents some limitations. The content of it-HBV DNA is expressed in IU/mg of liver tissue instead of quantity/cells. Although the samples were 10 mg each, there still could be considerable variation in the number of cells per biopsy sample. Furthermore, the expression of quantity in IU/mg may render difficult external comparison of levels from previous assays.
Another limitation is that there are no patients harbouring HBV genotype G and only few with genotype B. These genotypes are not widespread in Europe. It would be advisable to collect and test them in future studies.
In conclusion, the described modification of the commercially available assay, COBAS ® Ampliprep/COBAS ® TaqMan HBV test v2.0, represents a simple and accurate method for quantification of it-HBV DNA. The widespread usage of such versatile assay could extend the possibility to determine the quantitative levels of it-HBV DNA to a larger number of patients in the setting of chronic and occult HBV infection and can pose the basis for studies, addressed to a better definition of the correlation between serological HBV marker and intrahepatic viral load.
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